Clinical Trial Update: FLT3-ITD Targeted Therapy in Fit AML Patients [Phase 2, Phase 3]

View source ↗

Summary

An early-phase trial update on a FLT3-ITD targeted therapy for fit patients with acute myeloid leukemia, involving Phase 2 and Phase 3 studies that are not yet …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Myeloid Leukemia

Snippet

Sponsor: European Organisation for Research and Treatment of Cancer - EORTC | Conditions: AML (Acute Myeloid Leukemia) | Phase 2, Phase 3 | Status: NOT_YET_RECRUITING